James Davis

Sep 1, 2024 | arxiv.org | James Davis |Tara Kelly

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Aug 27, 2024 | onlinelibrary.wiley.com | Utkarsh Goel |Danai Dima |James Davis |Nausheen Ahmed

What is the new aspect of your work? This multicenter retrospective study represents the largest case series describing the use of standard of care chimeric antigen receptor (CAR) T-cell therapy in patients with AL amyloidosis and concurrent relapsed/refractory multiple myeloma. What is the central finding of your work?

May 10, 2024 | davisjam.medium.com | James Davis

I am on the faculty of Electrical & Computer Engineering at Purdue University, where I research and teach coursework in software engineering. I was formerly a software engineer (QA) at IBM. Sometimes students ask me the following question: " How do I stay up-to-date in software engineering? "Here are my thoughts on the topic. Because it's the right thing to doIn case you're not aware, the two primary professional societies for the computing profession are the ACM and the IEEE .

Apr 11, 2024 | nature.com | Aimaz Afrough |Doris Hansen |Surbhi Sidana |Lauren C. Peres |Danai Dima |Joseph McGuirk | +6 more

Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [1]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [2].

Apr 7, 2024 | jacksonpost.news | Brandon Shields |James Davis

By James DavisGuest columnistIn 2015, JCM alumni came together as the school district’s Vision 2020 plan threatened closure of their alma mater. There was protesting outside of the board of education, a march, a petition, and many, many meetings in an effort to “Rebuild or Renovate JCM.”Despite the efforts, the school board voted to close JCM. Fast forward to 2021 when JCM got a second chance and re-opened its doors.